Cytosorbents Corp 8-K Summary: 2026 Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Cytosorbents Corp on August 13, 2026. The filing details the voting outcomes for five proposals submitted to shareholders, including director elections, executive compensation, auditor ratification, and a reverse stock split authorization.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
At the record date of June 15, 2026, there were 62,842,748 shares outstanding. A quorum was established with 42,487,327 shares represented. All five proposals were approved by the stockholders:
- Proposal 1 (Election of Directors): Five directors were elected. While all nominees received majority support, significant "Against" votes were recorded, ranging from approximately 2.3 million to 3.5 million shares per nominee.
- Proposal 2 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 21,831,424 votes "For" and 2,988,267 votes "Against."
- Proposal 3 (Auditor Ratification): The appointment of WithumSmith+Brown, PC was ratified with 41,517,193 votes "For" and 864,322 votes "Against."
- Proposal 4 (Reverse Stock Split): Shareholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split. The ratio is set between 1-for-5 and 1-for-20, with the exact ratio to be determined by the Board within one year of the meeting.
- Proposal 5 (Adjournment): The proposal to adjourn the meeting if necessary was approved, though no adjournment was required.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors. The primary operational implication is the authorization of a reverse stock split, which the Board may implement at its discretion within the next year to adjust the share count.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio once determined by the Board, as the filing only authorizes a range of 1-for-5 to 1-for-20.
- Review the significant "Against" votes cast for the director nominees and executive compensation to gauge shareholder sentiment regarding governance and pay.
- Confirm the timing of the reverse stock split implementation, as it could occur at any time within the one-year anniversary of the August 13, 2026 meeting.
- Note that the filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial health metrics.